SAB4200323

Anti-OSTF1 (C-terminal) antibody produced in rabbit

~1.0 mg/mL, affinity isolated antibody

• Synonym(s): Anti-OSF1, Anti-Osteoclast-stimulating factor 1
• UNSPSC Code: 12352203
• NACRES: NA.41

Properties

• biological source: rabbit
• conjugate: unconjugated
• antibody form: affinity isolated antibody
• antibody product type: primary antibodies
• clone: polyclonal
• form: buffered aqueous solution
• mol wt: antigen ~26 kDa
• species reactivity: human
• concentration: ~1.0 mg/mL
• technique(s): western blot: 1-2 μg/mL using lysates of HEK-293T cells over-expressing human OSTF1.
• UniProt accession no.: Q92882
• shipped in: dry ice
• storage temp.: −20°C
• target post-translational modification: unmodified
• Gene Information: human ... OSTF1(26578)

Description

General description

Osteoclast-stimulating factor (OSF or OSTF1) gene is mapped to human chromosome 9q21.13 and is expressed in osteoclasts (OCL) as well as motor neurons. OSF is a small intracellular protein and comprises an N-terminal proline-rich region SRC Homology 3 (SH3) domain, three ankyrin repeats and a C-terminal aspartate-rich region. Structurally, OCF protein takes up a β‐barrel fold.

Specificity

Anti-OSTF1 (C-terminal) recognizes human OSTF1.

Immunogen

peptide corresponding to the C- terminal region of human OSTF1 conjugated to KLH. The corresponding sequence differs by two or three amino acids in mouse or rat, respectively.

Application

Anti-OSTF1 (C-terminal) antibody produced in rabbit may be used in immunoblotting.

Biochem/physiol Actions

Osteoclast-stimulating factor (OSF or OSTF1) SRC Homology 3 (SH3) domain undergoes conformational changes to bind to proline-rich ligand. The C-terminal ankyrin repeats preferably binds to negative-charged binding partners. OSF-SH3 domain interaction stimulates OCL formation and its inhibition may reduce bone resorption by OCL. A compromised bone resorption functionality in OCL further triggers bone loss and may lead to various bone disorders, including hyperparathyroidism, Paget′s disease, osteoporosis, estrogen deficiency, periodontal disease as well as inflammatory bone loss and bone malignancy. OSF favors OCL formation by interacting with sarcoma proto oncogene (c-Src) and its associated proteins based signaling pathway. OSF is implicated in the pathophysiology of spinal muscular atrophy by its possible interaction with survival motor neuron (SMN) proteins through SH3 domain.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Storage and Stability

For continuous use, store at 2-8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing, or storage in “frost-free” freezers,is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.

Disclaimer

Unless otherwise stated in our catalog, our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Safety Information

• Storage Class: 10 - Combustible liquids
• flash_point_f: Not applicable
• flash_point_c: Not applicable